Candipoz® (Posaconazole) — Broad Spectrum Triazole Antifungal

First-Line Prophylaxis and Treatment for Invasive Fungal Infections in Immunocompromised Patients

Candipoz® (Posaconazole) is a broad-spectrum triazole antifungal agent used for prophylaxis and treatment of invasive fungal infections including invasive aspergillosis, invasive candidiasis, and fusariosis in immunocompromised patients. Posaconazole has one of the broadest antifungal spectrums of any azole antifungal — covering Aspergillus, Candida, Fusarium, Mucor, and many other fungal pathogens.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Candipoz (Posaconazole) to hospitals, haematology centres, oncology clinics, ICUs, and pharmacies across India. Manufactured by leading pharmaceutical companies, Candipoz is an essential antifungal medicine for immunocompromised patients including those receiving chemotherapy, stem cell transplantation, and prolonged corticosteroid therapy.

What is Candipoz (Posaconazole)?

Candipoz contains Posaconazole, a second-generation triazole antifungal structurally related to Itraconazole but with significantly broader antifungal activity. Posaconazole works by inhibiting the fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase — blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane.

Without ergosterol the fungal cell membrane becomes structurally compromised, leading to increased membrane permeability, leakage of cellular contents, and fungal cell death. Posaconazole’s broad spectrum includes organisms resistant to or not covered by Fluconazole and Itraconazole — particularly Mucorales (mould causing mucormycosis) and Aspergillus species.

Full prescribing information is available at the FDA label for Posaconazole.

Clinical Studies and Evidence

Cornely et al. Prophylaxis Trial (Posaconazole vs Fluconazole/Itraconazole in AML/MDS) Published in the New England Journal of Medicine (2007), this landmark trial demonstrated that Posaconazole prophylaxis significantly reduced invasive fungal infections compared to Fluconazole or Itraconazole in neutropenic patients with AML or MDS — with a breakthrough invasive fungal infection rate of 2% vs 8% — and significantly improved overall survival.

Ullmann et al. GVHD Prophylaxis Trial (Posaconazole vs Fluconazole in GVHD) Published in the New England Journal of Medicine (2007), this trial showed Posaconazole was superior to Fluconazole in preventing invasive fungal infections in haematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD) on immunosuppressive therapy.

Invasive Aspergillosis Studies Multiple studies have demonstrated Posaconazole’s efficacy as salvage therapy for invasive aspergillosis refractory to or intolerant of standard antifungal therapy, with overall response rates of 42% in heavily pre-treated patients.

Mucormycosis Studies Posaconazole has demonstrated activity against Mucorales species — the causative organisms of mucormycosis — making it one of the few antifungals with proven activity against this life-threatening infection.

Available Strengths

Candipoz is available in the following formulations:

• 100mg Gastro-resistant Tablets (delayed-release)
• 40mg/mL Oral Suspension

Important: The delayed-release tablet formulation provides significantly higher and more consistent plasma levels than the oral suspension and is the preferred formulation for prophylaxis and treatment when available.

Indications — What Candipoz is Used For

Prophylaxis:

• Prevention of invasive Aspergillus and Candida infections in patients at high risk due to:
  • Severely immunocompromised patients such as those receiving remission-induction chemotherapy for AML or MDS
  • Haematopoietic stem cell transplant (HSCT) recipients receiving high-dose immunosuppressive therapy for GVHD

Treatment:

• Treatment of invasive aspergillosis in patients refractory to or intolerant of Amphotericin B or Itraconazole
• Treatment of Fusariosis in patients refractory to or intolerant of Amphotericin B
• Treatment of Chromoblastomycosis and Mycetoma refractory to Itraconazole
• Treatment of Coccidioidomycosis refractory to Amphotericin B, Itraconazole, or Fluconazole
• Treatment of oropharyngeal candidiasis including cases refractory to Itraconazole or Fluconazole

For detailed indication information refer to NCI Posaconazole Drug Information or MedlinePlus Posaconazole.

Key Benefits of Candipoz

Broadest Antifungal Spectrum of Any Oral Azole Posaconazole covers Aspergillus, Candida (including azole-resistant species), Fusarium, Mucorales (Mucor, Rhizopus), Cryptococcus, and many other fungal pathogens — making it the most versatile oral antifungal available.

Only Oral Azole Active Against Mucorales Posaconazole is unique among oral azoles in having activity against Mucorales species — the causative organisms of mucormycosis, a rapidly fatal infection in immunocompromised patients.

Proven Survival Benefit in High-Risk Patients The Cornely et al. trial demonstrated not only reduced invasive fungal infections but also improved overall survival with Posaconazole prophylaxis in AML/MDS patients — one of the few antifungal agents to demonstrate a survival benefit.

Standard of Care for High-Risk Prophylaxis Posaconazole is recommended as first-line prophylaxis in neutropenic AML/MDS patients and HSCT recipients with GVHD in international guidelines including IDSA and ESCMID guidelines.

Oral Administration Oral availability eliminates the need for IV antifungal prophylaxis in outpatient settings — reducing hospitalisation burden and improving patient convenience.

How Candipoz Works

Fungal cell membranes contain ergosterol — a sterol unique to fungi that is essential for membrane integrity and function. The ergosterol biosynthesis pathway involves the enzyme lanosterol 14α-demethylase (CYP51) which converts lanosterol to ergosterol.

Candipoz works by:

• Inhibiting the fungal cytochrome P450 enzyme lanosterol 14α-demethylase (CYP51)
• Blocking the conversion of lanosterol to ergosterol
• Causing accumulation of toxic methylated sterol precursors in the fungal membrane
• Disrupting fungal cell membrane integrity and permeability
• Leading to leakage of essential cellular components and fungal cell death

Posaconazole’s broader spectrum compared to Fluconazole and Itraconazole is due to its ability to fit into the active site of a wider range of fungal CYP51 enzymes — including those from Aspergillus, Fusarium, and Mucorales species.

For a detailed antifungal mechanism overview refer to the Infectious Diseases Society of America (IDSA) guidelines.

Candipoz vs Other Antifungals — Spectrum Comparison

Dosage and Administration

Prophylaxis (Tablets):

• 300mg (three 100mg tablets) twice daily on day 1 (loading dose)
• Then 300mg once daily from day 2 onwards

Prophylaxis (Oral Suspension):

• 200mg (5mL) three times daily — take with food or nutritional supplement

Treatment of Invasive Infections (Tablets):

• 300mg twice daily on day 1 (loading dose)
• Then 300mg once daily

Treatment (Oral Suspension):

• 400mg (10mL) twice daily with food

Key Administration Points:

• Delayed-release tablets should be swallowed whole — do not crush, chew, or break
• Oral suspension should be shaken well before use
• Take with food or a nutritional supplement to maximise absorption (particularly important for oral suspension)

Full dosing guidelines available at Drugs.com Posaconazole Dosage.

Who Should Use Candipoz

Candipoz is prescribed for:

• Haematology patients receiving intensive chemotherapy for AML or MDS — antifungal prophylaxis during neutropenia
• HSCT recipients with GVHD on high-dose immunosuppression — antifungal prophylaxis
• Patients with invasive aspergillosis refractory to standard antifungal therapy
• Patients with mucormycosis or other rare fungal infections
• Patients with oropharyngeal candidiasis refractory to standard azole therapy
• Severely immunocompromised patients including those on prolonged high-dose corticosteroids

Candipoz is prescribed by haematologists, oncologists, infectious disease specialists, and intensivists. A.K. Pharma supplies Candipoz to hospitals, haematology centres, ICUs, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include nausea, vomiting, diarrhoea, abdominal pain, headache, fever, and elevated liver enzymes.

Serious side effects include:

• Hepatotoxicity — monitor liver function tests before and during treatment
• QTc prolongation — monitor ECG in patients with cardiac risk factors or on QT-prolonging medications
• Serious drug interactions — particularly with immunosuppressants (Tacrolimus, Cyclosporine, Sirolimus) and other CYP3A4 substrates
• Adrenal insufficiency — rare cases reported with prolonged use

Full side effect information available at FDA Posaconazole Safety Information.

Precautions and Drug Interactions

Posaconazole is a strong CYP3A4 inhibitor with significant drug interactions:

• Tacrolimus, Cyclosporine, Sirolimus — levels markedly increased — dose reduction and therapeutic drug monitoring required
• Midazolam and other benzodiazepines — levels significantly increased — avoid or use with extreme caution
• Statins metabolised by CYP3A4 (e.g. Atorvastatin, Simvastatin) — levels increased — consider dose reduction
• Rifampicin, Phenytoin, Carbamazepine — significantly reduce Posaconazole levels — avoid concomitant use
• Proton pump inhibitors — reduce Posaconazole absorption from oral suspension — use tablets where possible
• Monitor liver function tests at baseline and during treatment
• Monitor ECG in patients at risk of QTc prolongation

Storage and Handling

Tablets:

• Store at room temperature below 30°C
• Keep in original packaging

Oral Suspension:

• Store at room temperature below 25°C
• Do not freeze
• Shake well before use
• Use within 4 weeks of opening

As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Candipoz under manufacturer-recommended conditions ensuring product integrity for every supply.

Manufacturer Information

Candipoz (Posaconazole) is manufactured by leading Indian and international pharmaceutical companies producing the generic Posaconazole formulation. The originator Posaconazole (Noxafil) was developed by Merck (MSD) and received FDA approval in September 2006. A.K. Pharma supplies only genuine Candipoz sourced from authorized distributors.

Related Anti Fungal and Cancer Medicines Available at A.K. Pharma

• Ambisome 50mg (Amphotericin B) — liposomal Amphotericin B for severe fungal infections
• Venclexta (Venetoclax) — BCL-2 inhibitor for AML and CLL
• Azadine (Azacitidine) — hypomethylating agent for MDS and AML
• Browse all Anti Fungal Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Candipoz used for? Candipoz (Posaconazole) is used for prophylaxis of invasive fungal infections in high-risk immunocompromised patients and for treatment of invasive aspergillosis, fusariosis, and other fungal infections refractory to standard therapy. More information available at MedlinePlus.

Q. What is the generic name of Candipoz? The generic name of Candipoz is Posaconazole. It belongs to the triazole antifungal class of medicines.

Q. How is Candipoz different from Fluconazole? Candipoz (Posaconazole) has a significantly broader antifungal spectrum than Fluconazole — covering Aspergillus, Mucorales, and Fusarium which are not covered by Fluconazole. Posaconazole is also active against Fluconazole-resistant Candida species making it suitable for high-risk immunocompromised patients.

Q. Is Candipoz active against mucormycosis? Yes. Posaconazole is one of the few oral antifungals with proven activity against Mucorales species — the causative organisms of mucormycosis. It is used as salvage therapy and step-down oral treatment in mucormycosis patients.

Q. Is Candipoz available in India? Candipoz can be supplied to hospitals, haematology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Candipoz in India? Candipoz price in India varies by formulation and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Candipoz from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Candipoz in bulk? Yes. A.K. Pharma supplies Candipoz in bulk to hospitals, haematology centres, ICUs, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Candipoz from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Candipoz sourced from authorized distributors
• Reliable supply to hospitals, haematology centres, and ICUs across India
• Bulk supply available with competitive pricing
• Prompt response to all quote requests
• Serving haematologists and infectious disease specialists across Delhi NCR and India

Contact A.K. Pharma for Candipoz Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in